Breast Cancer

Clinical Trials

Appointment New Patient Appointment or 214-645-8300

To learn more about Breast Cancer Clinical Trials and eligibility, please visit or email us at

Featured Breast Cancer Clinical Trial

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-Negative Breast Cancer:

The purpose of this research study is to determine how two drugs together – nivolumab and ipilimumab – work in treating breast cancer that has spread to other parts of the body. The investigators also want to understand whether certain DNA or protein markers in the blood or tumor tissue may indicate whether the combination will work in future patients.

Nivolumab is called an anti-PD-1 or a checkpoint inhibitor and is an antibody designed to allow the body's own immune system to destroy tumors. Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent your body's immune system from stopping to fight this specific cancer.

We seek patients who have either triple negative breast cancer or hormone receptor positive breast cancer with more than 10 mutations per megabase of DNA as determined on molecular testing report (such as through Foundation Medicine, TEMPUS, Caris testing, etc.) that has spread to other parts of the body and has not yet been treated or has been treated but not responded.